Zanubrutinib (Brukinsa) is made by BeiGene USA, Inc.
The Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib (Brukinsa) with obinutuzumab for relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy on March 7, 2024. BeiGene USA, Inc. is the manufacturer of this medication.
